Career history of Randal A. Hassler
Former positions of Randal A. Hassler
| Companies | Position | Start | End |
|---|---|---|---|
Seattle Biomedical Research Institute
 Seattle Biomedical Research Institute Miscellaneous Commercial ServicesCommercial Services Seattle Biomedical Research Institute operates as a non-profit organization that researches and discovers infectious diseases. It provides research for new drugs, vaccines, and diagnostics. The company was founded by Kenneth D. Stuart and Ruth W. Shearer in 1976 and is headquartered in Seattle, WA. | Chief Operating Officer | 2007-12-31 | 2013-12-31 |
| Director of Finance/CFO | 2010-11-21 | 2013-12-31 | |
| AMGEN INC. | Corporate Officer/Principal | 1994-12-31 | 2006-12-31 |
| ALDER BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | 2014-07-31 | - |
Training of Randal A. Hassler
| Indiana University | Undergraduate Degree |
| Colorado State University | Graduate Degree |
Statistics
International
| United States | 6 |
Operational
| Corporate Officer/Principal | 2 |
| Chief Operating Officer | 1 |
| Director of Finance/CFO | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| AMGEN INC. | Health Technology |
| Private companies | 2 |
|---|---|
Seattle Biomedical Research Institute
Seattle Biomedical Research Institute Miscellaneous Commercial ServicesCommercial Services Seattle Biomedical Research Institute operates as a non-profit organization that researches and discovers infectious diseases. It provides research for new drugs, vaccines, and diagnostics. The company was founded by Kenneth D. Stuart and Ruth W. Shearer in 1976 and is headquartered in Seattle, WA. | Commercial Services |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
- Stock Market
- Insiders
- Randal A. Hassler
- Experience
